Gp100 (25-33), mouse TFA is a 9-amino acid MHC I epitope peptide derived from human melanocyte glycoprotein 100/PMEL. Gp100 (25-33), mouse TFA binds to MHC I molecules such as H-2Db and is presented to CD8+ T cells to activate specific CTLs and induce IFN-γ release. Gp100 (25-33), mouse TFA enhances T cell surveillance and anti-tumor immune responses through antigen presentation experiments. Gp100 (25-33), mouse TFA can be used for research on melanoma antigen presentation, CTL expansion, ELISPOT/ICS/tetramer assays, and peptide vaccines/adoptive immunotherapy[1-4].
In vitro, EL-4 cells pulsed with 1μM Gp100 (25-33), mouse TFA for 2 hours can trigger IFN-γ release from 2gp100-reactive CD8⁺ T cells during co-culture, leading to T cell recognition and lysis of the EL-4 cells[5]. Bone marrow-derived dendritic cells were pulsed with 1μg/mL Gp100 (25-33), mouse TFA for 2 hours. Gp100 (25-33), mouse TFA enabled dendritic cells to carry the Gp100(25-33) epitope for vaccination, stimulated Tc1 cytokine production including IFN-γ, IL-2, and TNF-α[6]. PMEL1 mouse splenocytes incubated with 1μM Gp100 (25-33), mouse TFA for 2 days exert cytotoxic effects against cancer cells when co-cultured with B16F0 and YUMM1.7 cells[7].
In vivo, C57BL/6 mice bearing B16F10 melanoma received intradermal injection of 50μg/100μL cationic liposome-conjugated Gp100 (25-33), mouse TFA in the inguinal region on days 10, 17, and 24. The mice received intraperitoneal injection of 100μg/100μL anti-PD-1 monoclonal antibody on days 11, 15, 19, and 23. Gp100 (25-33), mouse TFA increased the number of IFN-γ-secreting CD8+ T cells and tumor-infiltrating lymphocytes in tumors, enhanced specific lysis of B16F10 target cells by CTLs, delayed tumor growth[8]. C57BL/6 mice bearing B16 melanoma and immunized with hgp100 DNA received intraperitoneal injection of 100μg Gp100 (25-33), mouse TFA every 2 days for 7 times. Gp100 (25-33), mouse TFA failed to elicit specific CTL responses, failed to inhibit B16 melanoma growth[9]. C57BL/6 mice receiving CD8+ T cells from pmel-1-TCR transgenic mice received intradermal injection of PLGA nanoparticles containing 10μg Gp100 (25-33), mouse TFA. Gp100 (25-33), mouse TFA increased the number of hgp100-specific CD8+ T cells in draining lymph nodes, increased the number of lymph node T cells[10].
References:[1] Xie J, Yang C, Liu Q, et al. Encapsulation of Hydrophilic and Hydrophobic Peptides into Hollow Mesoporous Silica Nanoparticles for Enhancement of Antitumor Immune Response. Small. 2017 Oct;13(40).
[2] Prins RM, Shu CJ, Radu CG, et al. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother. 2008 Sep;57(9):1279-89.
[3] Benkhoucha M, Molnarfi N, Belnoue E, et al. In-vivo gp100-specific Cytotoxic CD8+ T Cell Killing Assay. Bio Protoc. 2018 Nov 20;8(22):e3082.
[4] Zhu X, Nishimura F, Sasaki K, et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007 Feb 12;5:10.
[5] Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998 Jul 20;188(2):277-286.
[6] He H, Wisner P, Yang G, et al. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med. 2006 Jun 13;4:24.
[7] Klinke D, Gould A, Pirkey A, et al. A functional comparison of two transplantable syngeneic mouse models of melanoma: B16F0 and YUMM1.7. Biology Open. 2025;14:bio062175.
[8] Yazdani M, Hatamipour M, Alani B, et al. Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy. Iran J Basic Med Sci. 2020;23(8):1065-1077.
[9] Gold J, Ferrone C, Guevara-Patino J, et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol. 2003 May 15;170(10):5188-94.
[10] Zhang Z, Tongchusak S, Mizukami Y, et al. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials. 2011;32(14):3666-78.